Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for December 05, 2013 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   



Mitchell Finer to Speak at Cell & Gene Therapy Feb 20-21, 2014 in San Diego, CA

Mitchell Finer, Chief Scientific Officer of bluebird bio To Give a Featured Presentation at the Inaugural Cell and Gene Therapy Conference (Feb 20-21, 2014 in San Diego, CA)
 
x-small text small text medium text large text

    SAN DIEGO, CA, December 05, 2013 /24-7PressRelease/ -- Mitchell Finer, Chief Scientific Officer of bluebird bio, will give a featured presentation on the topic of cell and gene therapy for rare diseases at the Inaugural Cell and Gene Therapy Conference on February 20-21, 2014 in San Diego, CA by GTC.

bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, is in a recently-initiated phase 2/3 study for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in a phase 1/2 study in France for the treatment of beta-thalassemia major and severe sickle cell disease. A second phase 1/2 study with LentiGlobin in the United States has been initiated for the treatment of beta-thalassemia major. bluebird bio also has an early-stage chimeric antigen receptor-modified T cell (CAR-T) program for oncology in partnership with Celgene Corporation (source: bluebird bio, inc.)

Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, it is important to stay up-to-date with the evolving regulatory challenges and pre-clinical requirements for drug development and discovery. This meeting brings together experts from industry and academia to discuss the development and applications of cell and gene therapy as well as strategies and challenges for commercialization.

This conference is also part of the Future Biotech Summit 2014, which consists of this conference, and two other additional co-located conferences:
Cell & Gene Therapy
2nd Orphan Drugs Research & Commercialization
Ubiquitin Research & Drug Discovery

For more information, please visit http://www.gtcbio.com

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.



---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from Kristen Starkey:

Contact Information:
Kristen Starkey
GTCbio

San Diego, CA
United States
Voice: 626-256-6405
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.